Evidence map›Paper›PMID 33452397›Full record

ArticleScientific reports2021

Semiconducting polymer nanoparticles for photothermal ablation of colorectal cancer organoids.

Bryce McCarthy, Amit Cudykier, Ravi Singh, Nicole Levi-Polyachenko, Shay Soker

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Chemical reviews · 2022
    Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Bryce McCarthyDepartment of Plastic and Reconstructive Surgery Research, Wake Forest School of Medicine, Winston Salem, NC, USA.
Amit CudykierWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
Ravi SinghDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Nicole Levi-PolyachenkoDepartment of Plastic and Reconstructive Surgery Research, Wake Forest School of Medicine, Winston Salem, NC, USA. nlevi@wakehealth.edu.
Shay SokerVirginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA. ssoker@wakehealth.edu.
Forest Institute · USVirginia Tech - Wake Forest University School of Biomedical Engineering & Sciences · USWake Forest University · US

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
NCATS NIH HHS UL1 TR001420NCI NIH HHS R01 CA207222NIH HHS UL1TR001420
6 · The paper itself

Abstract

Colorectal cancer (CRC) treatment is currently hindered by micrometastatic relapse that cannot be removed completely during surgery and is often chemotherapy resistant. Targeted theranostic nanoparticles (NPs) that can produce heat for ablation and enable tumor visualization via their fluorescence offer advantages for detection and treatment of disseminated small nodules. A major hurdle in clinical translation of nanoparticles is their interaction with the 3D tumor microenvironment. To address this problem tumor organoid technology was used to evaluate the ablative potential of CD44-targeted polymer nanoparticles using hyaluronic acid (HA) as the targeting agent and coating it onto hybrid donor acceptor polymer particles (HDAPPs) to form HA-HDAPPs. Additionally, nanoparticles composed from only the photothermal polymer, poly[4,4-bis(2-ethylhexyl)-cyclopenta[2,1-b;3,4-b']dithiophene-2,6-diyl-alt-2,1,3-benzoselenadiazole-4,7-diyl] (PCPDTBSe), were also coated with HA, to form HA-BSe NPs, and evaluated in 3D. Monitoring of nanoparticle transport in 3D organoids revealed uniform diffusion of non-targeted HDAPPs in comparison to attenuated diffusion of HA-HDAPPs due to nanoparticle-matrix interactions. Computational diffusion profiles suggested that HA-HDAPPs transport may not be accounted for by diffusion alone, which is indicative of nanoparticle/cell matrix interactions. Photothermal activation revealed that only HA-BSe NPs were able to significantly reduce tumor cell viability in the organoids. Despite limited transport of the CD44-targeted theranostic nanoparticles, their targeted retention provides increased heat for enhanced photothermal ablation in 3D, which is beneficial for assessing nanoparticle therapies prior to in vivo testing.

Indexed as

Ablation TechniquesAnimalsCell Line, TumorCell SurvivalColorectal NeoplasmsHyaluronan ReceptorsHyaluronic AcidHyperthermia, InducedIndolesMiceNeoplasm Recurrence, LocalOrganoidsPhotochemotherapyPhotothermal TherapyPolymersQuantum DotsCD44 protein, humanHyaluronan ReceptorsHyaluronic AcidIndolespoly(2,6-(4,4-bis(2-ethylhexyl)-4H-cyclopenta(2,1-b-3,4-b0)dithiophene))-alt-4,7-(2,1,3-benzothiadiazole)PolymersThiadiazoles

Identifiers

PMID33452397
PMCPMC7810691
OpenAlexW3126081818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.